Home 2019-02-20T12:13:45+00:00


At M4K Pharma, we are using open science to revolutionize how affordable new treatments are discovered and developed. Through our Medicines4Kids program, we will aggregate and align the work of global academics, foundations and industry researchers to advance new cures for childhood diseases not well-served by current business models.

M4K Pharma’s Data:
In line with M4K Pharma’s open science principles, we are committed to sharing our research data freely in the public domain. Our data is currently available for public viewing in the video recordings of our monthly open scientific updates, which are posted to our Blog and also available through our YouTube Channel. Data will be openly available in a downloadable format soon.

Missed our March meeting? Here's the full recording https://t.co/I7PrNDnhRC

Open science is good business. We structured @M4KPharma and @M4NDpharma to access gov’t & foundation funding, but not VC funds. Annual gov’t & foundation funding for health R&D is 10x greater that annual health VC funding. #openscience companies have far more funding options.

Alfredo Picado @thesgconline designs a synthetic route for promiscuous inhibitors of ALK2, a #DIPG and #FOP target: https://t.co/Oh1BbQQVA0 @FOPFriends @DefeatDIPG @AbbiesArmy @M4KPharma @BrainTumourOrg

Ellie Williams @thesgconline investigates how phosphorylation events affect the activity of mutant forms of ALK2 driving #FOP and #DIPG. #Openscience notebook: https://t.co/WLLtKjaO7m Blog: https://t.co/CmU4OOGwjk @FOPFriends @DefeatDIPG @AbbiesArmy @M4KPharma @BrainTumourOrg

If you are a scientist and are interested in using M4K2009 in your studies get in touch either with us, @M4KPharma or @thesgconline https://t.co/fiux423kKU

Load More...

Latest Blog Posts